NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

vertex.com ↗
—
Latest disclosed NPS
no score published
0
NPS entries
0 with a number
105%
NRR
11 Feb 2026
95%
GRR
7 May 2026

In their words

“NRR was 112%, up 2 full percentage points compared to last year's first quarter”
— David DeStefano, President and CEO, Vertex Pharmaceuticals Incorporated · Earnings call, Q1 2024 · 8 May 2024
“Our gross revenue retention rate, or GRR, was 95.6% at quarter end”
— John Schwab, CFO, Vertex Pharmaceuticals Incorporated · Earnings call, Q1 2022 · 10 May 2022
“Our gross revenue retention rate, or GRR, was 95% at quarter end”
— John Schwab, CFO, Vertex Pharmaceuticals Incorporated · Earnings call, Q4 2021 · 9 Mar 2022

NPS disclosures (0)

Search the database →

No NPS disclosures yet.

Retention disclosures (39)

Open in the retention database →

5 Aug 2026
Retention95%

Vertex maintained gross revenue retention of 95% in Q2 2026.

— reported by finance.yahoo.com · 5 Aug 2026
finance.yahoo.com ↗
5 Aug 2026
Retention105%

Vertex maintains robust net revenue retention of 105% and gross retention of 95%, demonstrating resilience in its tax automation niche.

— reported by seekingalpha.com · 5 Aug 2026
seekingalpha.com ↗
28 Jul 2026
Retention105%

Vertex reported a Net Revenue Retention rate of 105%.

— reported by seekingalpha.com · 28 Jul 2026
seekingalpha.com ↗
30 Jun 2026
Retention105%

Vertex reported a net revenue retention rate of 105% in Q1 2026, down 4 percentage points from 109% year-over-year.

— reported by intellectia.ai · 30 Jun 2026
intellectia.ai ↗
30 Jun 2026
Retentiondown

Vertex reported a decline in net revenue retention, though strong sales and free cash flow growth offset the metric's weakness in Q1 2026.

— reported by finance.yahoo.com · 30 Jun 2026
finance.yahoo.com ↗
9 May 2026
Retention95%

Vertex Q1 beat and raised guidance with gross revenue retention stable at 95% and net revenue retention held steady.

— reported by chartmill.com · 9 May 2026
chartmill.com ↗
8 May 2026
Retention105%

Vertex reported Q1 2026 net revenue retention (NRR) of 105%, down from 109% a year prior, with gross revenue retention of 95%.

— reported by fidelity.com · 8 May 2026
fidelity.com ↗
7 May 2026
GRR95%

Gross revenue retention: 95% (Q1 2026) — “Gross Revenue Retention Rate 95% as of March 31, 2026 and 95% as of March 31, 2025.”

— Vertex Pharmaceuticals Incorporated · SEC 10-Q quarterly report · filed 7 May 2026
SEC 10-Q quarterly report ↗
11 Feb 2026
GRR94%

Gross revenue retention: 94% (Q4 2025) — “Gross Revenue Retention ("GRR") was 94%, compared to 95% at both December 31, 2024.”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 11 Feb 2026
SEC 8-K filing ↗
11 Feb 2026
NRR105%

Net revenue retention: 105% (Q4 2025) — “Net Revenue Retention ("NRR") was 105%, compared to 109% at December 31, 2024.”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 11 Feb 2026
SEC 8-K filing ↗
3 Nov 2025
NRR107%

Net revenue retention (direct customers): 107% (Q3 2025) — “Net Revenue Retention ("NRR") was 107%, compared to 111% at September 30, 2024”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 3 Nov 2025
SEC 8-K filing ↗
6 Aug 2025
NRR108%

Net revenue retention (direct customers): 108% (Q2 2025) — “Net Revenue Retention ("NRR") was 108%, compared to 110% at June 30, 2024”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 6 Aug 2025
SEC 8-K filing ↗
27 Feb 2025
GRR95%

Gross revenue retention (direct customers): 95% (Q4 2024) — “Gross Revenue Retention ("GRR") was 95%, consistent with both December 31, 2023, and September 30, 2024”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 27 Feb 2025
SEC 8-K filing ↗
27 Feb 2025
NRR109%

Net revenue retention (direct customers): 109% (Q4 2024) — “Net Revenue Retention ("NRR") was 109%, compared to 113% at December 31, 2023”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 27 Feb 2025
SEC 8-K filing ↗
6 Nov 2024
NRR111%

Net revenue retention (direct customers): 111% (Q3 2024) — “Net Revenue Retention ("NRR") was 111%, compared to 111% at September 30, 2023, and 110% at June 30, 2024.”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 6 Nov 2024
SEC 8-K filing ↗
7 Aug 2024
NRR110%

Net revenue retention (direct customers): 110% (Q2 2024) — “Net Revenue Retention ("NRR") was 110%, compared to 111% at June 30, 2023, and 112% at March 31, 2024.”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 7 Aug 2024
SEC 8-K filing ↗
8 May 2024
NRR112%

Net revenue retention: 112% (Q1 2024) — “NRR was 112%, up 2 full percentage points compared to last year's first quarter”

— David DeStefano, President and CEO, Vertex Pharmaceuticals Incorporated · Earnings call, Q1 2024 · 8 May 2024
Earnings call, Q1 2024 ↗
23 Apr 2024
NRR112%

Net revenue retention: 112% (Q1 2024) — “Net revenue retention at March 31, 2024 is expected to be between 111% and 113%”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 23 Apr 2024
SEC 8-K filing ↗
29 Feb 2024
GRR95%

Gross revenue retention (direct customers): 95% (December 31, 2023) — “Gross Revenue Retention ("GRR") was 95%, compared to 96% at both December 31, 2022”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 29 Feb 2024
SEC 8-K filing ↗
29 Feb 2024
NRR113%

Net revenue retention (direct customers): 113% (December 31, 2023) — “Net Revenue Retention ("NRR") was 113%, compared to 110% at December 31, 2022”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 29 Feb 2024
SEC 8-K filing ↗
9 Aug 2023
NRR111%

Net revenue retention: 111% (Q2 2023) — “As of June 30, 2023 Net Revenue Retention Rate 111% (2022: 110%)”

— Vertex Pharmaceuticals Incorporated · SEC 10-Q quarterly report · filed 9 Aug 2023
SEC 10-Q quarterly report ↗
8 Mar 2023
GRR96%

Gross revenue retention: 96% (Q4 2022) — “Gross Revenue Retention ("GRR") was 96%, an increase from 95% at December 31, 2021”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 8 Mar 2023
SEC 8-K filing ↗
8 Mar 2023
NRR110%

Net revenue retention: 110% (Q4 2022) — “Net Revenue Retention ("NRR") was 110%, an increase from 108% at December 31, 2021”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 8 Mar 2023
SEC 8-K filing ↗
9 Nov 2022
GRR96%

Gross revenue retention (direct customers): 96% (Q3 2022) — “Gross Revenue Retention ("GRR") was 96% in the third quarter of 2022, an increase from 95% for the quarter ended September 30, 2021”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 9 Nov 2022
SEC 8-K filing ↗
9 Nov 2022
NRR109%

Net revenue retention (direct customers): 109% (Q3 2022) — “Net Revenue Retention ("NRR") was 109% in the third quarter of 2022, an increase from 106% for the quarter ended September 30, 2021”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 9 Nov 2022
SEC 8-K filing ↗
9 Aug 2022
GRR96%

Gross revenue retention: 96% (June 30, 2022) — “Gross Revenue Retention Rate 96 % (2022) vs 94 % (2021)”

— Vertex Pharmaceuticals Incorporated · SEC 10-Q quarterly report · filed 9 Aug 2022
SEC 10-Q quarterly report ↗
10 May 2022
NRR110%

Net revenue retention: 110% (Q1 2022) — “For the three months ended March 31, 2022: Net Revenue Retention Rate 110%. The 500 basis point increase in NRR to 110% at March 31, 2022 from 105% for the same period in 2021”

— Vertex Pharmaceuticals Incorporated · SEC 10-Q quarterly report · filed 10 May 2022
SEC 10-Q quarterly report ↗
10 May 2022
GRR96%

Gross revenue retention: 96% (Q1 2022) — “Our gross revenue retention rate, or GRR, was 95.6% at quarter end”

— John Schwab, CFO, Vertex Pharmaceuticals Incorporated · Earnings call, Q1 2022 · 10 May 2022
Earnings call, Q1 2022 ↗
9 Mar 2022
NRR108%

Net revenue retention: 108% (Q4 2021) — “Net Revenue Retention ("NRR") rate was 108% in the fourth quarter of 2021, an increase from 106% in both the December 31, 2020”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 9 Mar 2022
SEC 8-K filing ↗
9 Mar 2022
GRR95%

Gross revenue retention: 95% (Q4 2021) — “Our gross revenue retention rate, or GRR, was 95% at quarter end”

— John Schwab, CFO, Vertex Pharmaceuticals Incorporated · Earnings call, Q4 2021 · 9 Mar 2022
Earnings call, Q4 2021 ↗
11 Aug 2021
GRR94.3%

Gross revenue retention: 94.3% (Q2 2021) — “Our gross revenue retention rate or GRR was 94.3% at quarter end which excludes the internal migrations by customers to our cloud solutions, which were approximately 4%”

— John Schwab, Chief Financial Officer, Vertex Pharmaceuticals Incorporated · Earnings call, Q2 2021 · 11 Aug 2021
Earnings call, Q2 2021 ↗
13 May 2021
NRR105%

Net revenue retention: 105% (Q1 2021) — “NRR from 109% for the three months ended March 31, 2020 to 105% for the same period in 2021”

— Vertex Pharmaceuticals Incorporated · SEC 10-Q quarterly report · filed 13 May 2021
SEC 10-Q quarterly report ↗
13 May 2021
GRR95%

Gross revenue retention: 95% (Q1 2021) — “Our gross revenue retention rate or GRR was 95% at quarter end, which excludes the impact of existing customers migrating to our cloud solutions, which was approximately 4%”

— John Schwab, CFO, Vertex Pharmaceuticals Incorporated · Earnings call, Q1 2021 · 13 May 2021
Earnings call, Q1 2021 ↗
10 Mar 2021
NRR108%

Net revenue retention: 108% (FY2020) — “has averaged 108% over the last four quarters”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 10 Mar 2021
SEC 8-K filing ↗
10 Mar 2021
NRR106%

Net revenue retention: 106% (Q4 2020) — “Net Revenue Retention Rate was 106% in the fourth quarter of 2020”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 10 Mar 2021
SEC 8-K filing ↗
10 Mar 2021
GRR91%

Gross revenue retention: 91% (FY2020) — “Our gross revenue retention remained at 91%, which is consistent throughout the 2020 quarters.”

— John Schwab, Chief Financial Officer, Vertex Pharmaceuticals Incorporated · Earnings call, Q4 2020 · 10 Mar 2021
Earnings call, Q4 2020 ↗
9 Sep 2020
NRR108%

Net revenue retention: 108% (Q2 2020) — “Net Revenue Retention Rate ("NRR") was 108%, which was consistent on a year-over-year basis.”

— Vertex Pharmaceuticals Incorporated · SEC 8-K filing · filed 9 Sep 2020
SEC 8-K filing ↗
9 Sep 2020
GRR91%

Gross revenue retention: 91% (Q2 2020) — “Our gross revenue retention rate in the quarter was 91%, which is consistent with many of the prior periods.”

— John Schwab, Chief Financial Officer, Vertex Pharmaceuticals Incorporated · Earnings call, Q2 2020 · 9 Sep 2020
Earnings call, Q2 2020 ↗
2 Jul 2020
NRR109%

Net revenue retention: 109% (FY2019) — “Our NRR was 109% as of December 31, 2019 and March 31, 2020.”

— Vertex Pharmaceuticals Incorporated · SEC S-1 IPO prospectus · filed 2 Jul 2020
SEC S-1 IPO prospectus ↗

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.